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Gamma delta T cells expressing the Vg9Vδ2 T cell recep-
tor (TCR) are the most predominant gδ-T cell subset in
peripheral blood accounting for approximately 1-5 % of all
T cells. Vg9Vδ2 T cells recognize phosphoantigens (pAg)
such as isopentenyl pyrophosphate (IPP), a naturally
occurring pAg that can accumulate in tumor cells, result-
ing in activation, cytokine release and anti-tumor activity
of Vg9Vδ2 T. The use of Vg9Vδ2 T cells in clinical trials,
either via adoptive transfer of ex vivo expanded Vg9Vδ2
T cells or through in vivo activation by aminobisphospho-
nates or synthetic pAg, has led to promising results. Anti-
tumor responses were observed in some patients, but
overall results lack consistency. This might be related to
systemic activation of Vg9Vδ2 T cells in these trials, not
providing a specific trigger for these cells to accumulate at
the tumor site.
In order to improve the efficacy of Vg9Vδ2 T cell based
immunotherapy, we focused on the design of a tumor-
targeting construct that binds both the TCR of Vg9Vδ2 T
cells and the Epidermal Growth Factor Receptor (EGFR),
which is over-expressed by many tumor types, including
Vg9Vδ2 T cell susceptible tumors like colon carcinoma
and head and neck cancer. For this bi-specific construct
an antagonistic anti-EGFR single domain antibody frag-
ment (VHH or Nanobody) and an agonistic anti-Vg9Vδ2
TCR VHH were identified, characterized and constructed
into a bi-specific targeting molecule. Only when bound to
both EGFR expressing tumor cells and Vg9Vδ2 T cells,
this bi-specific targeting molecule induced Vg9Vδ2 T cell
activation, release of IFN-g and TNF-a as well as up-
regulated expression of cytolytic molecules such as
perforin-and granzyme B. Importantly, tumor targeted
Vg9Vδ2 T cells were able to efficiently lyse EGFR
expressing tumor cells in vitro.
This study shows that bi-specific anti-Vg9Vδ-T-anti-
EGFR-nanobodies can specifically and efficiently lyse
EGFR-expressing tumor cells and are promising candi-
dates for cancer immunotherapy.
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